国信证券认为，建议关注拥有差异化创新能力，产品具备全球商业化潜力的创新药公司，以及新签 订单、在手订单高增长的头部CDMO公司。看好创新药长期逻辑，关注底部反转标的。推荐低估值、具 备业绩拐点或业绩提速预期的器械公司。 每日经济新闻 截至13:19，A股三大指数集体回落，上证指数跌0.75%，深证成指跌0.76%，创业板指跌1.68%。科 创医药ETF基金（588130）上涨4.28%，最新报价1.195元，换手率13.94%。成分股涨跌互现，三生国健 领涨20.00%，泽璟制药-U上涨15.50%，益方生物-U上涨14.08%，迈威生物-U上涨11.54%，荣昌生物上 涨10.14%；皓元医药领跌4.80%，奕瑞科技下跌1.59%，佰仁医疗下跌1.14%，澳华内镜下跌0.59%，爱 博医疗下跌0.40%。 （责任编辑：贺翀 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

截至13:19，A股三大指数集体回落，上证指数跌0.75%，深证成指跌0.76%，创业板指跌1.68%。科创医 药ETF基金（588130）上涨4.28%，最新报价1.195元，换手率13.94%。成分股涨跌互现，三生国健领涨 20.00%，泽璟制药-U上涨15.50%，益方生物-U上涨14.08%，迈威生物-U上涨11.54%，荣昌生物上涨 10.14%；皓元医药领跌4.80%，奕瑞科技下跌1.59%，佰仁医疗下跌1.14%，澳华内镜下跌0.59%，爱博 医疗下跌0.40%。 （文章来源：每日经济新闻） 国信证券认为，建议关注拥有差异化创新能力，产品具备全球商业化潜力的创新药公司，以及新签订 单、在手订单高增长的头部CDMO公司。看好创新药长期逻辑，关注底部反转标的。推荐低估值、具备 业绩拐点或业绩提速预期的器械公司。 ...

银河证券研报认为，医药板块估值经历较长时间调整，近期已呈现显著结构性修复趋势，但公募基金重 仓持仓水平仍低于历史均值，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药 械有望获益。 值得关注的产品，及截至发稿涨跌幅： 格隆汇10月31日｜今日，回调多日的创新药板块全面上攻，港股的映恩生物涨超12%，三生制药涨超 11%，科伦博泰生物和信达生物涨超8%，带动科创医药ETF基金、恒生医药ETF涨超3%。 消息面上： ①中美关系缓和降低潜在扰动，叠加今年对外授权交易持续出现进展，尤其是四季度BD旺季开启，如 近期信达生物达成超百亿大额BD。此外，信达生物公布Q3共取得总产品收入超33亿元，同比保持约 40%的强劲增长. ②产业积极动态不断，三生制药合作方辉瑞启动PD-1/VEGF双抗两项全球三期临床；国产创新药在10月 ESMO会议上数据亮眼，12月还有ASH（国国液学学会）、圣安东尼奥乳腺癌大会等行业会议。 ③2025年国家医保谈判10月30日在北京开启。今年国谈在延续医保目录常规调整机制的基础上，首次正 式引入"商保创新药目录"机制。 全球医药全产业链代表：恒生医药ETF(159892)，+ ...

消息面上： ①中美关系缓和降低潜在扰动，叠加今年对外授权交易持续出现进展，尤其是四季度BD旺季开启，如 近期信达生物达成超百亿大额BD。此外，信达生物公布Q3共取得总产品收入超33亿元，同比保持约 40%的强劲增长. ②产业积极动态不断，三生制药合作方辉瑞启动PD-1/VEGF双抗两项全球三期临床；国产创新药在10月 ESMO会议上数据亮眼，12月还有ASH（国国液学学会）、圣安东尼奥乳腺癌大会等行业会议。 ③2025年国家医保谈判10月30日在北京开启。今年国谈在延续医保目录常规调整机制的基础上，首次正 式引入"商保创新药目录"机制。 今日，回调多日的创新药板块全面上攻，港股的映恩生物涨超12%，三生制药涨超11%，科伦博泰生物 和信达生物涨超8%，带动科创医药ETF基金、恒生医药ETF涨超3%。 银河证券研报认为，医药板块估值经历较长时间调整，近期已呈现显著结构性修复趋势，但公募基金重 仓持仓水平仍低于历史均值，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药 械有望获益。 值得关注的产品，及截至发稿涨跌幅： 全球医药全产业链代表：恒生医药ETF(159892)，+3.35%，同标的规 ...

按申万二级行业分类，科创医药ETF基金跟踪的指数权重集中于医疗器械（36.76%）、化学制药 （36.62%）、生物制品（18.84%）、医疗服务（4.32%）、医疗美容（2.03%）等板块。 截至9:56，A股三大指数涨跌互现，上证指数跌0.40%，深证成指涨0.09%，创业板指跌0.09%。科创医 药ETF基金（588130）上涨2.36%，最新报价1.173元，换手率6.15%。成分股方面涨跌互现，三生国健 领涨15.95%，博瑞医药上涨10.10%，微芯生物上涨6.94%，泽璟制药-U上涨6.91%，益方生物-U上涨 6.13%；神州细胞领跌5.68%，皓元医药下跌3.93%，佰仁医疗下跌1.26%，爱博医疗下跌1.01%，威高骨 科下跌0.71%。 股消息面上，10月30日，辉瑞在Clinicaltrials.gov网站上注册了PD-1/VEGF双抗PF-08634404（SSGJ- 707）的两项全球三期临床试验，分别为与化疗联合治疗晚期非小细胞肺癌（头对头对比Keytruda+化 疗）、与化疗联合治疗转移性结直肠癌。 此外，2025年国家医保谈判（国谈）正式启动，首次引入"商保创新药目录"机制， ...

Group 1 - Multiple domestic pharmaceutical companies, including Innovent Biologics and Hengrui Medicine, announced business development (BD) deals within two days, indicating a trend of increased collaboration in the industry [1] - Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, receiving an upfront payment of $1.2 billion, including a $100 million strategic equity investment, with potential milestone payments up to $10.2 billion [1] - Despite these positive developments, the Hong Kong innovation drug index fell over 1%, with a decline of more than 15% since October 8, contrasting sharply with previous market reactions to BD announcements [1] Group 2 - Analysts suggest that liquidity issues and valuation pressures from previous gains are causing a slowdown in the innovation drug sector, with the market showing less enthusiasm for BD transaction amounts [2][3] - The total amount of external licensing for Chinese innovative drugs surpassed $100 billion for the year, marking a historical milestone [2] - The sentiment in the pharmaceutical sector has returned to a more comfortable trading range, awaiting capital inflows [3] Group 3 - The focus remains on the international competitiveness of domestic innovative drugs and the trend of BD transactions abroad [5] - The U.S. pharmaceutical market has experienced volatility due to various pressures from the Trump administration, including threats of high tariffs on drugs [6] - Despite these pressures, the potential negative impacts on the industry are expected to be limited, with the narrative logic of BD transactions remaining intact [7] Group 4 - The upcoming quarterly reports are anticipated to show performance improvements, alongside the continued rollout of BD transactions [4] - The sentiment in the A-share pharmaceutical and biotechnology sector has dropped below the historical median, indicating a potential for recovery as market conditions stabilize [8]

Core Viewpoint - The innovation drug sector is a prominent investment theme this year, showing strong performance driven by policy support, global competitiveness, and commercial profitability [1][3][31]. Group 1: Market Performance - The Hang Seng Pharmaceutical ETF (159892) increased by 60% this year, while the STAR Pharmaceutical ETF (588130) rose by 10.9% in the last ten trading days [3][27]. - Despite a recent pullback, the innovation drug sector continues to dominate the ETF performance rankings [2][3]. Group 2: Driving Factors - Two main reasons for the strong performance of innovation drugs: improvement in the macroeconomic environment and favorable policy developments [4][5]. - The U.S. CPI in May was lower than expected, leading to increased market expectations for a potential interest rate cut by the Federal Reserve, which would benefit the valuation of innovation drug stocks [4]. Group 3: Market Dynamics - The innovation drug sector is experiencing a turning point characterized by macroeconomic recovery, industry fundamentals, and valuation adjustments [9][10]. - The latest PE ratio of the Hang Seng Biotechnology Index is 27.64, indicating room for further valuation recovery as it remains below the historical range of the past decade [11]. Group 4: Industry Developments - Recent approvals of 11 innovative drugs by the National Medical Products Administration signify a growing pipeline for domestic innovation drug companies [11][12]. - Successful international collaborations and participation in global events like the ASCO conference highlight the competitive strength of Chinese innovation drug firms [11][12]. Group 5: Liquidity and Investment Trends - The influx of foreign capital into the Hong Kong market is evident, with 27 companies listed this year, 15 of which attracted foreign cornerstone investors [19][20]. - The average daily trading volume in Hong Kong has significantly increased, reflecting heightened liquidity that benefits the innovation drug sector [25][27]. Group 6: Future Outlook - The innovation drug sector is expected to continue benefiting from a favorable macroeconomic environment, policy support, and increasing global competitiveness [31][34]. - The current growth cycle for innovation drugs is distinct due to the backdrop of macroeconomic recovery and industry value reassessment [33][34].

Core Viewpoint - The innovative drug sector is a significant investment theme this year, showing strong performance and potential for continued growth driven by macroeconomic improvements, supportive policies, and the realization of commercial profits [1][3][33]. Group 1: Market Performance - The Hang Seng Pharmaceutical ETF (159892) has risen by approximately 60% this year, indicating a strong recovery in the pharmaceutical sector after four years of downturn [3]. - Despite a recent pullback, the innovative drug sector continues to dominate the ETF performance rankings, with the Hang Seng Pharmaceutical ETF increasing by 4.18% and the Sci-Tech Pharmaceutical ETF (588130) by 2.21% [2][3]. Group 2: Drivers of Strength - Two main reasons for the strength of innovative drugs are the improving macroeconomic environment and favorable policy developments [4][5]. - The U.S. CPI in May was lower than expected, leading to increased market expectations for a potential 100 basis point rate cut by the Federal Reserve, which would benefit the valuation of innovative drug stocks [4]. - Recent policy initiatives, such as the improvement of basic medical insurance drug lists and the establishment of bio-manufacturing platforms, further support the innovative drug sector [5]. Group 3: Market Dynamics - The innovative drug sector has outperformed many other popular sectors over the past six months, indicating a shift in market sentiment [6]. - The concept of "turning points" is crucial, encompassing macroeconomic, industry, and company fundamentals, as well as valuation aspects [9][10]. - The current PE ratio of the Hang Seng Biotechnology Index is 27.64, suggesting that there is still room for valuation recovery as it remains below 90% of the historical range over the past decade [11]. Group 4: Growth Opportunities - The approval of multiple innovative drugs by the National Medical Products Administration, including 11 new drugs on May 29, highlights the growing pipeline and market potential for innovative drug companies [11][12]. - Successful international collaborations and the recognition of domestic innovative drugs at global events like the ASCO conference demonstrate the competitive strength of Chinese pharmaceutical companies [11][12]. Group 5: Liquidity and Investment Trends - The influx of foreign capital into the Hong Kong market, with 27 IPOs and 15 involving foreign cornerstone investors this year, indicates a reversal in sentiment towards Hong Kong stocks [19][20]. - The average daily trading volume in Hong Kong has significantly increased, reflecting heightened liquidity that benefits the innovative drug sector [25][27]. - Morgan Stanley projects continued high trading activity in Hong Kong, driven by increased A+H listings and potential capital inflows due to favorable monetary conditions [28]. Group 6: Future Outlook - The innovative drug sector is positioned for sustained growth, supported by a combination of policy, profitability, and internationalization [33]. - The current growth cycle is distinct due to the macroeconomic recovery, industry revaluation, and increased liquidity, leading to stronger-than-expected performance [35][36]. - However, not all companies will benefit equally, and only those with clinical value and commercialization capabilities are likely to thrive in the long term [37].

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...